Literature DB >> 21720740

Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.

Jinah Park1, Eunju Park, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Woo-Ho Kim, Do-Youn Oh, Yung-Jue Bang.   

Abstract

P-cadherin is frequently up-regulated in solid tumors such as gastric, colon, lung, pancreatic and breast cancers. Although P-cadherin promotes cadherin-mediated cell adhesion, the gastric cancer-linked regulation of P-cadherin has not been extensively investigated. In this study, we found epigenetic regulation of P-cadherin in human gastric cancer cells that was induced by treatment with DNA demethylating drug and histone deacetylase inhibitor. Silencing P-cadherin by using siRNA induces apoptosis in gastric cells and blocks expression of Tie-2, an angiogenic receptor tyrosine kinase. In contrast, ectopically expressed P-cadherin by generating P-cadherin stable cell line enhances Tie-2 expression and cell mobility. We also demonstrated that inhibition of P-cadherin by PF-03732010, a fully humanized anti-P-cadherin IgG1 monoclonal antibody, suppressed cell migration in vitro and tumor growth in BALB/c nude mice bearing SNU620 gastric cancer xenograft. The data reported here are the first to reveal that the inhibition of P-cadherin decreases tumor cell migration and blocks a tumorigenesis by down-regulation of Tie-2 in gastric cancer. This demonstrates the potential for P-cadherin to be used as a target for treatment of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720740     DOI: 10.1007/s10637-011-9710-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  25 in total

Review 1.  Validating cancer drug targets.

Authors:  John D Benson; Ying-Nan P Chen; Susan A Cornell-Kennon; Marion Dorsch; Sunkyu Kim; Magdalena Leszczyniecka; William R Sellers; Christoph Lengauer
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

3.  A sequencing method based on real-time pyrophosphate.

Authors:  M Ronaghi; M Uhlén; P Nyrén
Journal:  Science       Date:  1998-07-17       Impact factor: 47.728

4.  P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance.

Authors:  Min A Kim; Eun Ji Jung; Hye Seung Lee; Hee Eun Lee; Han-Kwang Yang; Do-Youn Oh; Yung-Jue Bang; Woo Ho Kim
Journal:  Hum Pathol       Date:  2010-03-16       Impact factor: 3.466

5.  Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.

Authors:  S H Song; H S Jong; H H Choi; H Inoue; T Tanabe; N K Kim; Y J Bang
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

6.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

Authors:  V Martin; J Xu; S K Pabbisetty; M M Alonso; D Liu; O-H Lee; J Gumin; K P Bhat; H Colman; F F Lang; J Fueyo; C Gomez-Manzano
Journal:  Oncogene       Date:  2009-05-04       Impact factor: 9.867

Review 8.  Tie2: a journey from normal angiogenesis to cancer and beyond.

Authors:  V Martin; D Liu; J Fueyo; C Gomez-Manzano
Journal:  Histol Histopathol       Date:  2008-06       Impact factor: 2.303

9.  Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors.

Authors:  T Nakayama; A Yoshizaki; N Kawahara; A Ohtsuru; C Y Wen; E Fukuda; M Nakashima; I Sekine
Journal:  Histopathology       Date:  2004-03       Impact factor: 5.087

Review 10.  P-cadherin expression in breast cancer: a review.

Authors:  Joana Paredes; Ana Luísa Correia; Ana Sofia Ribeiro; André Albergaria; Fernanda Milanezi; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  9 in total

1.  The X-ray structure of human P-cadherin EC1-EC2 in a closed conformation provides insight into the type I cadherin dimerization pathway.

Authors:  Andrea Dalle Vedove; Anna Paola Lucarelli; Valentina Nardone; Angelica Matino; Emilio Parisini
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

2.  Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer.

Authors:  Cunxi Li; Haiting Ma; Yang Wang; Zheng Cao; Ramona Graves-Deal; Anne E Powell; Alina Starchenko; Gregory D Ayers; Mary Kay Washington; Vidya Kamath; Keyur Desai; Michael J Gerdes; Lila Solnica-Krezel; Robert J Coffey
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

3.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

Review 4.  P-cadherin and the journey to cancer metastasis.

Authors:  André Filipe Vieira; Joana Paredes
Journal:  Mol Cancer       Date:  2015-10-06       Impact factor: 27.401

5.  The influence of the CHIEF pathway on colorectal cancer-specific mortality.

Authors:  Martha L Slattery; Abbie Lundgreen
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma.

Authors:  Melina Mescher; Peter Jeong; Sina K Knapp; Matthias Rübsam; Michael Saynisch; Marina Kranen; Jennifer Landsberg; Max Schlaak; Cornelia Mauch; Thomas Tüting; Carien M Niessen; Sandra Iden
Journal:  J Exp Med       Date:  2017-01-17       Impact factor: 14.307

7.  Disruption of cell adhesion by an antibody targeting the cell-adhesive intermediate (X-dimer) of human P-cadherin.

Authors:  Shota Kudo; Jose M M Caaveiro; Satoru Nagatoishi; Takamitsu Miyafusa; Tadashi Matsuura; Yukio Sudou; Kouhei Tsumoto
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

8.  A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.

Authors:  James J Harding; Ignacio Garrido-Laguna; Xiaoying Chen; Cynthia Basu; Afshin Dowlati; Alison Forgie; Andrea T Hooper; Cris Kamperschroer; Steven I Max; Allison Moreau; Megan Shannon; Gilbert Y Wong; David S Hong
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

9.  Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.

Authors:  Eduarda P Martins; Céline S Gonçalves; Marta Pojo; Rita Carvalho; Ana S Ribeiro; Vera Miranda-Gonçalves; Ricardo Taipa; Fernando Pardal; Afonso A Pinto; Carlos Custódia; Cláudia C Faria; Fátima Baltazar; Nuno Sousa; Joana Paredes; Bruno M Costa
Journal:  Mol Oncol       Date:  2022-06-10       Impact factor: 7.449

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.